• Researcher Profile

    Craig A. Bunnell, MD, MPH, MBA

     
    Craig A. Bunnell, MD, MPH, MBA

     
    Chief Medical Officer
    Institute Physician


    Assistant Professor of Medicine, Harvard Medical School

    Center/Program

    Breast Oncology

    Office phone: 617-632-3800
    Fax: 617-632-1930
    Email: craig_bunnell@dfci.harvard.edu

    Preferred contact method: appointment phone

    View Physician Profile
     
     

    Research Department

    Medical Oncology/Solid Tumor Oncology

    Interest

    Breast cancer, Quality of life, Symptom control

    Area of Research

    Novel Agents and Treatment Regimens for Breast Cancer

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

    Biography

    Dr. Bunnell received his MD from Harvard Medical School and his MPH from Harvard School of Public Health in 1990. He received his MBA from the Massachusetts Institute of Technology in 2008. He completed his residency in internal medicine and a fellowship in hematology and oncology at Brigham and Women's Hospital, where he also served as chief medical resident. He joined Dana-Farber in 1996, and is a member of the Breast Oncology Center in the Susan F. Smith Center for Women's Cancers. Dr. Bunnell was named Dana-Farber's Chief Medical Officer in 2012.

    Recent Awards

    • Bass Scholar, 2000

    Research

    Novel Agents and Treatment Regimens for Breast Cancer

    Our group has sought to advance the treatment of women with breast cancer through basic laboratory research, clinical trials, and correlative studies. We have conducted clinical treatment studies investigating the use of novel agents, innovative schedules, and combinations of established agents. Our group was the first to investigate the combination of trastuzumab and vinorelbine - a highly active and now standard therapy for women with HER2-positive advanced breast cancer. This combination is currently being investigated in the neoadjuvant, adjuvant, and metastatic settings. We also conducted some of the early trials of weekly taxane therapy.
    In the neoadjuvant setting, we have investigated various agents and combination regimens, including weekly trastuzumab with taxanes, vinorelbine, and letrozole. In addition, we studied novel intravenous agents such as the epothilone analogs, CCI-779, flavopiridol, and bevacizumab. Other clinical trials have investigated a number of new oral hormonal, chemotherapeutic, and biologic agents as well as their combinations, including ERA-923, UFT plus leucovorin, 5-fluorouracil (5-FU) plus eniluracil, oral vinorelbine, and OSI-776.
    To complement our treatment trials, we also have performed correlative basic science studies, which have sought to characterize HER2 signaling, assess markers of resistance, monitor response to therapy, and measure microscopic tumor burden. Other investigations have assessed patient compliance with oral chemotherapeutic regimens, evaluated patient attitudes and interest in participating in clinical trials, developed therapeutic agents and interventions to improve symptom control, and compared quality of life between various treatment options.

View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer
Research

Give Now